Rapid Tachyphylaxis of the Glucagon-Like Peptide 1–Induced Deceleration of Gastric Emptying in Humans
Open accessThe DOI matches its Crossref record; 35 of the 37 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Glucagon-like peptide (GLP)-1 lowers postprandial glycemia primarily through inhibition of gastric emptying. We addressed whether the GLP-1–induced deceleration of gastric emptying is subject to rapid tachyphylaxis and if so, how this would alter postprandial glucose control. RESEARCH DESIGN AND METHODS: Nine healthy volunteers (25 ± 4 years old, BMI: 24.6 ± 4.7 kg/m2) were examined with intravenous infusion of GLP-1 (0.8 pmol · kg−1 . min−1) or placebo over 8.5 h. Two liquid mixed meals were administered at a 4-h interval. Gastric emptying was determined, and blood samples were drawn frequently. RESULTS: GLP-1 decelerated gastric emptying significantly more after the first meal compared with the second meal (P = 0.01). This was associated with reductions in pancreatic polypeptide levels (marker of vagal activation) after the first but not the second meal (P < 0.05). With GLP-1, glucose concentrations declined after the first meal but increased after the second meal (P < 0.05). The GLP-1–induced reductions in postprandial insulin and C-peptide levels were stronger during the first meal course (P < 0.05). Likewise, glucagon levels were lowered by GLP-1 after the first meal but increased after the second test meal (P < 0.05). CONCLUSIONS: The GLP-1–induced delay in gastric emptying is subject to rapid tachyphylaxis at the level of vagal nervous activation. As a consequence, postprandial glucose control by GLP-1 is attenuated after its chronic administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Furthermore, GLP-1 can slow down gastric emptying by activating the vagus nerve, a part of the autonomic nervous system crucial for regulating the activities of the gastrointestinal tract.268”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [268]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 can slow down gastric emptying through its effects on smooth muscles and the nervous system in the gastrointestinal tract.264,268”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [268]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Data also suggest that there is tachyphylaxis with prolonged use of GLP‐1 RAs [29, 60]”
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The magnitude of effect on GE, unlike the effects on glycaemic control or appetite, is attenuated with prolonged GLP-1 exposure.[2][3][4]”
From The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP ‐1 receptor agonists (2020) · cites this paper as [3]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Native GIP mimicking postprandial GIP blood levels and GIPRAs did not reveal any relevant effects on GE. 3,[13][14][15]”
From The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP ‐1 receptor agonists (2020) · cites this paper as [3]
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 1×
“Although the glucose-lowering effect of GLP-1 in the fasting state is primarily mediated by its glucose-dependent augmentation of insulin secretion and inhibition of glucagon release (4,5), the key mechanism driving the postprandial normalization of glycemia by GLP-1 is a marked deceleration of gastric emptying leadin…”
BackgroundSelf-citationGarber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919 · cited 1×
“determined in ethanol-extracted plasma as previously described (15,18), using antiserum 89 390 for the measurement of intact GLP-1 [7–36 amide] plus cleavage products.”
MethodSelf-citationNauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817 · cited 2×
“fusion rate was based on previous studies (5,14) and was selected to increase”
BackgroundMethodSelf-citationTruncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670 · cited 1×
“A deceleration of gastric emptying by GLP-1 has been demonstrated in patients with type 2 diabetes and healthy individuals (5,8,14).”
BackgroundSelf-citationMitrakou, A., Kelley, D., Mokan, M., Veneman, T., Pangburn, T., Reilly, J., & Gerich, J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201023260104 · Cited by 595 · cited 1×
“This is in contrast with previous studies showing a significant decline in glucagon levels after intravenous or oral glucose ingestion (31,32).”
ResultEnhancing Incretin Action for the Treatment of Type 2 Diabetes
Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 579
Nauck, M. A. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.4.912 · Cited by 506 · cited 3×
“Given the importance of GIP as a physiologic incretin hormone (15,34), this might theoretically impair postprandial insulin responses and thus worsen glucose control.”
BackgroundMethodSelf-citationWillms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502
Self-citation
Cited by
Items 201–300 of 391
Giorgino, F., Bonadonna, R., Gentile, S., Vettor, R., & Pozzilli, P. (2016) · Diabetes/Metabolism Research Reviews · doi:10.1002/dmrr.2775 · Cited by 17
“caused by sustained plasma concentrations of the GLP-1 RA [29].”
BackgroundSmith, K., Davies, K. A. B., Stevenson, E., & West, D. J. (2020) · Frontiers in Nutrition · doi:10.3389/fnut.2020.587843 · Cited by 24
“This is important considering GLP-1-mediated regulation of gastric emptying and PPG are subjected to rapid tachyphylaxis following the incretin peptide’s sustained exposure (59, 60), where adaptive changes by which nutrients regulate gastrointestinal function have also been reported following prolonged intake of fat (…”
BackgroundGLP-1 receptor agonists in the context of cancer: the road ahead
Miousse, I. R. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00245.2025 · Cited by 23
Glucagon‐like peptide‐1: Are its roles as endogenous hormone and therapeutic wizard congruent?
Holst, J. J. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13433 · Cited by 25
Self-citationWan, S., McKie, P. M., Schirger, J. A., Slusser, J. P., Hodge, D. O., Redfield, M. M., Burnett, J. C. J., & Chen, H. H. (2016) · JACC Heart Failure · doi:10.1016/j.jchf.2015.12.014 · Cited by 20
“Tachyphylaxis remains a concern for peptide therapy, such as with the incretin hormone glucagon-like peptide (GLP)-1 (11,12).”
Approaches to obesity management
Sweeting, A., & Caterson, I. D. (2017) · Internal Medicine Journal · doi:10.1111/imj.13474 · Cited by 25
Suganuma, Y., Shimizu, T., Sato, T. K., Morii, T., Fujita, H., Sassa, M. H., & Yamada, Y. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13115 · Cited by 22
Aulifa, D. L., Adnyana, I. K., Levita, J., & Sukrasno, S. (2019) · Scientia Pharmaceutica · doi:10.3390/scipharm87040030 · Cited by 20
“This condition slows down gastric emptying, and reduces appetite [6,7].”
BackgroundJuel, C. T., Lund, A., Andersen, M. M., Hansen, C. P., Storkholm, J. H., Rehfeld, J. F., van Hall, G., Hartmann, B., Albrechtsen, N. J. W., Holst, J. J., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05158-9 · Cited by 21
“Lixisenatide is a short-acting GLP-1 receptor agonist and therefore less prone to tachyphylaxis when it comes to gastric emptying [33], thus providing sustained reductions of postprandial glucose concentrations during long-term use [34, 35].”
BackgroundSelf-citationAbdulraheem, A., Abujaber, B. A., Ayers, L., Zureikat, Q. A., Bashiri, K., Almhanni, G., Altork, N. A., Afzal, U., Qarkash, D., Spyros, P., et al. (2025) · Surgical Endoscopy · doi:10.1007/s00464-025-11962-4 · Cited by 23
Berg, J. K., Kim, E. H., Li, B. C., Joelsson, B. E., & Youssef, N. N. (2014) · BMC Gastroenterology · doi:10.1186/1471-230x-14-25 · Cited by 24
“Recently, rapid tachyphylaxis has been documented for GLP-1–dependent inhibition of gastric emptying in humans following prolonged infusion [50], prompting the question of whether the physiological effects of GLP-2 or teduglutide could also be affected by tachyphylaxis.”
BackgroundAulifa, D. L., Adnyana, I. K., Sukrasno, S., & Levita, J. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09501 · Cited by 24
Role of Point-of-Care Gastric Ultrasound in Advancing Perioperative Fasting Guidelines
Razak, A., Baburyan, S., Lee, E., Costa, A., & Bergese, S. D. (2024) · Diagnostics · doi:10.3390/diagnostics14212366 · Cited by 25
Advances in Pharmacologic Therapies for Type 2 Diabetes
Morsink, L., Smits, M., & Diamant, M. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0302-8 · Cited by 22
Proglucagon-derived peptides: human physiology and therapeutic potential
Gasbjerg, L. S., Nielsen, C. K., Suppli, M. P., Grøndahl, M. F. G., Holst, J. J., Knop, F. K., Jeppesen, P. B., & Lund, A. (2025) · Physiological Reviews · doi:10.1152/physrev.00057.2024 · Cited by 22
Self-citationEngineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases
Zeng, J., Tang, X., Qin, D., Yu, L., Zhou, X., Chi, F., Mi, J., Pan, H., Wu, J., Huang, B., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03677-4 · Cited by 28
Girges, C., Vijiaratnam, N., Athauda, D. S., Auld, G., Gandhi, S., & Foltynie, T. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00853-7 · Cited by 18
Kalas, M. A., Dang, T. Q., Galura, G. M., Alvarado, L. A., Dwivedi, A. K., Deoker, A., & McCallum, R. W. (2022) · Journal of Investigative Medicine · doi:10.1136/jim-2022-002480 · Cited by 16
Larsen, A. T., Karsdal, M. A., & Henriksen, K. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175837 · Cited by 16
Willson, C. M., Patel, L., Middleton, P., & Desai, M. M. (2024) · Cureus · doi:10.7759/cureus.58042 · Cited by 25
“Effects on vagal inhibition can be reduced significantly as early as the second dose of a GLP-1 agonist [22].”
BackgroundGLP-1 receptor agonists in the treatment of Type 2 diabetes
Bo, A.-R. (2013) · Diabetes Management · doi:10.2217/dmt.13.41 · Cited by 31
Tambascia, M. A., Malerbi, D. A. C., & Eliaschewitz, F. G. (2014) · Einstein (São Paulo) · doi:10.1590/s1679-45082014rb2862 · Cited by 23
Non-insulin pharmacological therapies for treating type 1 diabetes
Frandsen, C. S., Dejgaard, T. F., Madsbad, S., & Holst, J. J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1483339 · Cited by 18
“IDegLira have shown promising glucose lowering effects and weight loss in T2D (DUAL-studies) [113,114] and may be of interest to use as ‘basal’ insulin in obese persons with T1D still displaying some residual beta-cell function.”
BackgroundInfluentialSelf-citationGastrointestinal factors regulating lipid droplet formation in the intestine
Auclair, N., Melbouci, L., St-Pierre, D., & Levy, E. H. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.12.031 · Cited by 21
Dejgaard, T. F., Knop, F. K., Tarnow, L., Frandsen, C. S., Hansen, T. S., Almdal, T., Holst, J. J., Madsbad, S., & Andersen, H. U. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-007791 · Cited by 17
Self-citationPotential for Gut Peptide-Based Therapy in Postprandial Hypotension
Borg, M. J., Xie, C., Rayner, C. K., Horowitz, M., Jones, K. L., & Wu, T. (2021) · Nutrients · doi:10.3390/nu13082826 · Cited by 19
“Even though sustained stimulation of the GLP-1 receptor is known to be associated with tachyphylaxis for the slowing of gastric emptying by GLP-1 [46], there is recent evidence that exenatide QW [47] and semaglutide [48] may retain some capacity to slow gastric emptying in health and T2D with prolonged use.”
BackgroundDiffering effects of liraglutide on gastric emptying in Japanese patients with type 2 diabetes
Nagai, Y., Hashimoto, E., Oikawa, R., Asai, S., Terashima, Y., Nakamura, Y., Sasaki, Y., Tsukiyama, H., Fukuda, H., Ohshige, T., et al. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12247 · Cited by 16
“[11] reported that the extent of the delay in gastric emptying induced by liraglutide diminishes over time as a result of tachyphylaxis.”
BackgroundIncretins and the intensivist: what are they and what does an intensivist need to know about them?
Plummer, M. P., Chapman, M. J., Horowitz, M., & Deane, A. M. (2014) · Critical Care · doi:10.1186/cc13737 · Cited by 18
“The continuous activation of the GLP-1 receptor is thought to induce tachyphylaxis to the deceleration of gastric emptying, such that the slowing of gastric emptying diminishes markedly with long-term use, and consequently the lowering of postprandial glycaemia is only modest [53].”
BackgroundInter-relationships between gastric emptying and glycaemia: Implications for clinical practice
Murthy, T. A., Chapman, M. J., Jones, K. L., Horowitz, M., & Marathe, C. S. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i5.447 · Cited by 17
Torekov, S. S., Holst, J. J., & Ehlers, M. R. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12240 · Cited by 14
“In addition, tachyphylaxis of the GLP-1-induced delay in gastric emptying caused by continuous administration [14] may play a role.”
BackgroundSelf-citationAlbèr, A., Brønden, A., & Knop, F. K. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12911 · Cited by 15
Discovery of the GI Effects of GLP-1: An Historical Perspective
Holst, J. J. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07519-3 · Cited by 15
“Similarly, today’s longacting approved GLP-1 receptor agonists (RA)s (dulaglutide, liraglutide, semaglutide) inhibit gastric emptying, though tachyphylaxis to this effect develops within hours [24], with little effect left after chronic therapy, whereas their actions on glucose metabolism persist.”
BackgroundSelf-citationEvolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
Galstyan, G. R., Анатольевна, К. Е., & Александровна, Ю. Е. (2017) · Diabetes Mellitus · doi:10.14341/dm8804 · Cited by 20
“Угнетение моторики желудочно-кишечного тракта и замедление скорости опорожнения желудка, вероятно, опосредовано блуждающим нервом [12].”
Onishi, Y., Niemoeller, E., Ikeda, Y., Takagi, H., Yabe, D., & Seino, Y. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12275 · Cited by 13
Panchal, S., Mahmud, N., Atkins, J. H., Kang, H., Leto, A. C., Goebel, A. M., Trivedi, N., Chatila, A. T., Hsu, W.-W., Ginsberg, G. G., et al. (2025) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2025.01.004 · Cited by 17
Mahadevan, A., Vosooghi, A., Arora, J. S., Kumar, R. S., Singh, G., Tsai, K. K., & Quandt, Z. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf703 · Cited by 16
Furusawa, S., Nomoto, H., Oba‐Yamamoto, C., Takeuchi, J., Ito, M., Kurihara, H., Aoki, S., Miya, A., Kameda, H., Nakamura, A., et al. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej23-0648 · Cited by 18
Liraglutide Pretreatment Does Not Improve Acute Doxorubicin-Induced Cardiotoxicity in Rats
Tonon, C., Monte, M. G., Balin, P. S., Fujimori, A. S., Ribeiro, A. P. D., Ferreira, N. F., Vieira, N. M., Cabral, R. P., Okoshi, M., Okoshi, K., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115833 · Cited by 10
“However, approximately 7 days after initiating liraglutide, rats started to gain body weight, suggesting adaptation to the drug, as observed by other researchers [47–49].”
ResultBiology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection
Yau, K., Odutayo, A., Dash, S., & Cherney, D. Z. I. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.007 · Cited by 21
Simonds, S. E., Pryor, J. T., Koegler, F. H., Buch-Rasmussen, A. S., Kelly, L. E., Grove, K. L., & Cowley, M. A. (2019) · Diabetes · doi:10.2337/db18-1149 · Cited by 14
Umpierrez, G. E., Pasquel, F. J., Duggan, E. W., & Galindo, R. J. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241231565 · Cited by 19
From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists
Dave, B. P., Chorawala, M. R., Shah, I., Shah, N. N., Bhagat, S. U., Prajapati, B. G., & Thakkar, P. C. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09793-y · Cited by 17
The impact of glucagon-like peptide-1 receptor agonist on the gastric residue in upper endoscopy
Abu‐Freha, N., Levi, Z., Nevo-Shor, A., Guterman, R., Elhayany, R., Yitzhak, A., Yovel, D. Z., Cohen, D. L., & Shirin, H. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111900 · Cited by 15
Fano, M. D., Porcellati, F., Fanelli, C. G., Corio, S., Mazzieri, A., Lucidi, P., Bolli, G. B., & Bassotti, G. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110828 · Cited by 15
Giorgino, F., Yu, M., Haupt, A., Milicevic, Z., & García-Pérez, L. (2019) · Diabetes, obesity and metabolism · doi:10.1111/dom.13844 · Cited by 11
Wong, E., Cope, R. J., Dima, L., & Nguyen, T. K. (2022) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001588 · Cited by 17
Urva, S., Levine, J. A., Schneck, K. B., & Tang, C. C. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2322072 · Cited by 12
“46,47 Patients who are on a stable regimen of GLP-1 RAs are likely to have already established GI tolerability by the time switching to tirzepatide is considered.”
BackgroundThe Gut: A Key to the Pathogenesis of Type 2 Diabetes?
Holst, J. J., Pedersen, J., Albrechtsen, N. J. W., & Knop, F. K. (2017) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2017.0015 · Cited by 12
Self-citationJiang, Y., Bai, H., Liu, G., Wang, S.-Y., Yin, L., Hou, Z.-T., Zhao, C., & Fan, G. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1347684 · Cited by 12
“GLP-1RA also reduced body weight in patients with inadequately controlled T2DM, which was related to the activity of GLP-1 on central and peripheral receptors in the brain and stomach (43 – 45).”
Raccah, D. (2013) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.12.82 · Cited by 12
Kaineder, K., Birngruber, T., Rauter, G., Obermüller, B., Eichler, J., Münzker, J., Al-Zoughbi, W., Mautner, S., Torekov, S. S., Hartmann, B., et al. (2017) · International Journal of Obesity · doi:10.1038/ijo.2017.98 · Cited by 15
Lu, J. N., & Willars, G. B. (2019) · Biochemical Journal · doi:10.1042/bcj20180853 · Cited by 12
Acylated Ghrelin and The Regulation of Lipid Metabolism in The Intestine
Auclair, N., Patey, N., Melbouci, L., Ou, Y., Tomaz, L. M., Sané, A. T., Garofalo, C., Levy, E. H., & St-Pierre, D. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-54265-0 · Cited by 11
Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes
Ito, D., Iuchi, T., Kurihara, S., Inoue, I., Katayama, S., & Inukai, K. (2015) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2237w · Cited by 11
Lixisenatide – A New Glucagon-like Peptide 1 Receptor Agonist in the Treatment of Type 2 Diabetes
Vidal, J. (2010) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2013.09.02.76 · Cited by 15
Inoue, M., Shiramoto, M., Oura, T., Nasu, R., Nakano, M., & Takeuchi, M. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0605-7 · Cited by 11
“tying significantly after the first meal compared with the second meal [10].”
BackgroundBolli, G. B., Porcellati, F., & Meier, J. J. (2020) · Diabetes Care · doi:10.2337/dci20-0038 · Cited by 11
Self-citationAlqifari, S. F., Komi, O. A., Esmail, A., Alkhawami, K., Yousri, S., Muqresh, M. A., Alharbi, N., Khojah, A. A. A., Aljabri, A. M., Allahham, A., et al. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i3.331 · Cited by 11
Jin, J., Cui, G., Mi, N., Wu, W., Zhang, X., Xiao, C., Wang, J., Qiu, X., Han, M., Li, Z., et al. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106448 · Cited by 10
Trust the Gold Standard: All Glucagon-like Peptide-1 Receptor Agonists Can Delay Gastric Emptying.
Weber, M. (2023) · Anesthesiology · doi:10.1097/aln.0000000000004752 · Cited by 9
Lunati, M. E., Grancini, V., Colombo, C., Palmieri, E., Resi, V., Perrino, M., Orsi, E., & Fugazzola, L. (2015) · Metabolism · doi:10.1016/j.metabol.2015.09.010 · Cited by 12
Hirsch, I. B., Buse, J. B., Leahy, J. L., McGill, J. B., Peters, A. L., Rodbard, H. W., Rubin, R. R., Skyler, J. S., Verderese, C. A., & Riddle, M. C. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12136 · Cited by 11
“extended-release (exenatide QW), liraglutide, albiglutide and dulaglutide] results in less effective control of postprandial glucose, but better control of fasting glucose due to their overnight action [48].”
BackgroundTanaka, K., Okada, Y., Tokutsu, A., & Tanaka, Y. (2022) · Scientific Reports · doi:10.1038/s41598-021-04149-z · Cited by 11
Therapy for Obesity Based on Gastrointestinal Hormones
Bagger, J. I., Christensen, M., Knop, F. K., & Vilsbøll, T. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.339 · Cited by 13
“On top of this, the effects of gastric emptying do not explain the weight-reducing effects of GLP-1R agonists, as the effect of GLP-1 on the gastrointestinal motility wanes with time in contrast to the continuing effect on appetite and food intake [39, 40].”
BackgroundTolerance develops toward GLP-1 receptor agonists’ glucose-lowering effect in mice
Sedman, T., Krass, M., Rünkorg, K., Vasar, E., & Volke, V. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173443 · Cited by 11
Guo, Z., Wu, Y., Zhu, L., Wang, Y., Wang, D., & Sun, X. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00908-1 · Cited by 9
“The delayed gastric emptying induced by GLP-1 is influenced by a rapid response at the level of vagal activation, and the delay in gastric emptying by GLP-1 is significantly attenuated after long-term administration of GLP1 analogues[23], which was also consistent with the changes in intake of the intervention groups…”
ResultAhmed, M., Badi, S., Elidrisi, A., Husain, N. E., Zainudin, S. B., Mahmood, A., Abubaker, N. E., Alghamdi, A., & Ahmed, M. H. (2022) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-022-01145-6 · Cited by 11
Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C
SKOLNIK, N., Bonnes, H., Yeh, H., & Katz, A. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1173514 · Cited by 12
NUEVOS FÁRMACOS EN DIABETES MELLITUS
Aylwin, C. G. (2016) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2016.04.013 · Cited by 19
“En contraste, la acción sobre el VG de los agonistas prolongados se pierde en el tiempo, lo que se atribuye a un fenómeno de taquifilaxis (43) resultando en un menor impacto prandial (30).”
BackgroundUmpierrez, G., Pantalone, K., Atisso, C., Landó, L. F., & Patel, H. (2018) · Diabetes, obesity and metabolism · doi:10.1111/dom.13662 · Cited by 7
Meier, J. J., Bardtrum, L., CHENG, A. Y. Y., Malling, B., Montanya, E., Wagner, L., & Pratley, R. E. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14957 · Cited by 9
“A delay in gastric emptying following treatment with a GLP-1RA(20) has also been proposed as a possible mechanism of action; however, this is this is unlikely, due to tachyphylaxis seen following chronic GLP-1 administration.(21) In this analysis, data were derived from large phase 3 trials covering different study po…”
MethodSelf-citationEmerging role of insulin with incretin therapies for management of type 2 diabetes
Ahluwalia, R., & Vora, J. (2011) · Diabetes Therapy · doi:10.1007/s13300-011-0005-0 · Cited by 12
GLP-1 receptor agonist tachyphylaxis and perioperative recommendations
Wu, F., Klapman, S. A., Everett, L. L., Kuo, B., & Hobai, I. A. (2024) · British Journal of Anaesthesia · doi:10.1016/j.bja.2024.04.049 · Cited by 11
Nomoto, H., Oba‐Yamamoto, C., Takahashi, Y., Takeuchi, J., Nagai, S., Yokoyama, H., Taneda, S., Kurihara, Y., Aoki, S., Kameda, H., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00986-9 · Cited by 9
Targeting the Gut in Obesity: Signals from the Inner Surface
Petersen, N., Greiner, T. U., Torz, L., Bookout, A. L., Gerstenberg, M. K., Castorena, C. M., & Kuhre, R. E. (2022) · Metabolites · doi:10.3390/metabo12010039 · Cited by 11
Tolerance Does Not Develop Toward Liraglutide’s Glucose-Lowering Effect
Sedman, T., Vasar, E., & Volke, V. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00199 · Cited by 9
Another milestone in the evolution of GLP-1-based diabetes therapies
Nauck, M. A., Quast, D. R., & Meier, J. J. (2021) · Nature Medicine · doi:10.1038/s41591-021-01394-7 · Cited by 7
Self-citationPaggers, L., Mesotten, D., & Stragier, H. (2024) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000002103 · Cited by 8
Ukwade, D., Hernandez, L. J., Modi, Z. N., Raza, H. S., Siegel, M., Nwachukwu, D., Sarraf, P., Memon, A. A., Booth, M., Cooper, K., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1638981 · Cited by 15
Holt, J., Sandsdal, R. M., Byberg, S., Janus, C., Juhl, C. R., Jørgensen, J. R., Hartmann, B., Stallknecht, B. M., Holst, J. J., Madsbad, S., et al. (2025) · Obesity · doi:10.1002/oby.70043 · Cited by 8
“The increased late-phase postprandial GLP-1 with exercise was associated with improved late-phase postprandial glucose metabolism, likely due to GLP-1's dual role in stimulating insulin secretion and slowing gastric emptying [21, 22].”
Self-citationEffects of exenatide and liraglutide on 24-hour glucose fluctuations in type 2 diabetes
Nagakura, J., Yamakawa, T., Taguri, M., Tsuchiya, H., Shigematsu, E., Suzuki, J., Morita, S., Kadonosono, K., & Terauchi, Y. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej15-0500 · Cited by 7
Shaefer, C. F. (2016) · Clinical Diabetes · doi:10.2337/diaclin.34.2.81 · Cited by 7
“It has been widely hypothesized that a key driver for postprandial normalization of glycemia by GLP-1 receptor agonists is a marked deceleration of gastric emptying, resulting in delayed entry of glucose into the circulation (30).”
BackgroundIncretins in the Therapy of Diabetic Kidney Disease
Przezak, A., Bielka, W., & Pawlik, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212312 · Cited by 7
“They have a superior impact on fasting glucose level and HbA1c than shortacting agents but do not preserve the ability to delay gastric emptying, probably because of tachyphylaxis resulting from consistent receptor activation [50,51].”
Gastric point‐of‐care ultrasound in the GLP‐1 receptor agonist era: clinical impact and competency
Kelly, D. N., Pentyala, S., & Haskins, S. C. (2025) · Anaesthesia · doi:10.1111/anae.16548 · Cited by 6
“The authors did not specify the semaglutide doses or treatment durations, which is crucial since delayed gastric emptying from GLP-1 receptor agonists may diminish over time due to tachyphylaxis and may be dose-dependent [14, 15].”
Wang, B., Su, Z., Kuang, M., Luo, Y., Xu, M., Sun, M., Liu, X., Guo, Y., Bai, L., Wang, Y., et al. (2025) · Biomedical Materials · doi:10.1088/1748-605x/adb2cf · Cited by 6
“In addition, it has been revealed that the activation of GLP-1 receptors in the hypothalamus can create a feeling of satiety, leading to a decrease in food intake and weight loss [14].”
Traitement du diabète de type 2 : l’exénatide à libération prolongée
Guerci, B., & Sauvanet, J. (2014) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(14)70734-5 · Cited by 6
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2166-6755 · Cited by 7
“Analysis of recurrent events (including outcome of coronary events, hospitalisation for heart failure, hospitalisation for other reasons) and cardiovascular mortality showed significant reduc - tions with empagliflozin compared to placebo [129].”
Self-citationKitazawa, T., Yokoyama, K., & Kubota, K. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12423 · Cited by 6
Nakagawa, T., Nagai, Y., Yamamoto, Y. L., Miyachi, A., Hamajima, H., Mieno, E., Takahashi, M., Inoue, E., & Tanaka, Y. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107892 · Cited by 7
Potnuru, P. P., Hernandez, N., Nwokolo, O. O., & Sen, S. (2024) · British Journal of Anaesthesia · doi:10.1016/j.bja.2024.05.043 · Cited by 6
Elezz, A. M. A., khalefa, K. A., Gadelmawla, A. F., Khattab, Y. A., & Zeid, M. A. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01873-0 · Cited by 8
“Fluctuating levels of the drug in short-acting formulations, in addition to their effects on delaying gastric emptying, have been suggested as possible mechanisms of nausea (Pratley et al. 2014; Nauck et al. 2011).”
Palzes, V. A., Costales, B., Sterling, S., Kline‐Simon, A. H., Leggio, L., & Farokhnia, M. (2025) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2025.100659 · Cited by 8
Ridge, T. (2018) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000114 · Cited by 6
Bolli, G. B., Porcellati, F., Lucidi, P., Fanelli, C. G., Perseghin, G., Horowitz, M., & Owens, D. R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16616 · Cited by 6
“76 The more recent weekly FRC IcoSema 11 may prove useful in those people who are on the weekly BI icodec already, or are candidates for it, and need to improve PPG.”
Body Weight Gain and Hyperphagia After Administration of SGLT-2 Inhibitor: A Case Report
Hamamoto, H., & Noda, M. (2015) · American Journal of Case Reports · doi:10.12659/ajcr.896233 · Cited by 6
“It causes a lesser degree of gastrointestinal adverse effects because of tachyphylaxis 1-2 months after starting the medication [8].”
BackgroundThe Role of Insulin Resistance in Cardiorenal Metabolic Syndrome
Xiao, J., Song, W. L., Huang, Y., He, X., Weng, Y., & Yu, H. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001048 · Cited by 5
Wang, Y., Liu, J., Verbeke, K., Gasaly, N., Akkerman, R., & de Vos, P. (2026) · Advances in Nutrition · doi:10.1016/j.advnut.2026.100647 · Cited by 11
“…does not necessarily translate into clinical resistance in vivo because receptor recycling and heterogeneous GLP-1R expression across tissues may preserve efficacy, although some effects, particularly those mediated by gastric and neuronal pathways, can attenuate over time [132,134].”
Aronson, R. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2013.842465 · Cited by 5
Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus
Hanefeld, M., Raccah, D., & Monnier, L. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1251579 · Cited by 5
“control by GLP-1 seems to be attenuated after chronic exposure to high GLP-1 concentrations [68].”
BackgroundSu, Y., Zhang, S., Wu, Z., Liu, W.-T., Chen, J., Deng, F., Chen, F., Zhu, D., & Hou, K. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1054946 · Cited by 5
Metadata
- Authors
- Nauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J.
- Affiliations
- Diabeteszentrum Bad Lauterberg (DE)
- Conservative Emergency Room, Klinikum Krefeld, Krefeld, Germany
- University of Copenhagen (DK)
- St. Josef-Hospital (DE)
- Corresponding author
- Nauck, Michael A.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2011-04-23
- Volume
- 60
- Issue
- 5
- Pages
- 1561-1565
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3292331
- OpenAlex
- W2163229244
- Cited by
- 392
- References
- 37
- Citations by year
- 2026: 35 · 2025: 32 · 2024: 38 · 2023: 23 · 2022: 18 · 2021: 22 · 2020: 21 · 2019: 23 · 2018: 20 · 2017: 17 · 2016: 24 · 2015: 26 · 2014: 33 · 2013: 42 · 2012: 11
- FWCI
- 24.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- glucagon-like peptide-1, tachyphylaxis, gastric emptying, postprandial glucose control, vagal activation, pancreatic polypeptide, insulin secretion, glucagon, C-peptide, mixed meal
- MeSH terms
- Adult, Blood Glucose, C-Peptide, Gastric Emptying, Glucagon, Humans, Male, Tachyphylaxis, Postprandial Period, Glucagon-Like Peptide 1, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.